ConductScience.org, home

Paper42414740

Development and validation of a radiomics nomogram for predicting outcomes following combined radiotherapy and modern chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: a multicenter study.

Gong J and 18 others. Ann Hematol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Development and validation of a radiomics nomogram for predicting outcomes following combined radiotherapy and modern chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: a multicenter study. Papers, record 42414740. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42414740

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Development and validation of a radiomics nomogram for predicting outcomes following combined radiotherapy and modern chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: a multicenter study.
PubMed
Journal
Ann Hematol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Multicenter Study, Validation Study
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-10-10
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gong JJie
2Zhou YYongchun
3Gao SShan
4Liu QQiufang
5Liu JJingYi
6Wei YYanchun
7Zhang YYanqun
8Liu CChanghao
9Hou BBingxin
10Zhang LLei
11Li XXiaolong
12Dong HHongjuan
13Feng JJuan
14Ren JJingjing
15Su NNing
16Zhang MMai
17Zhao LLina
18Shi MMei
19Zang JJianhttps://orcid.org/0009-0001-1251-977X

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ChemoradiotherapyMajor topic
Lymphoma, Extranodal NK-T-CellMajor topic
NomogramsMajor topic
RadiomicsMajor topic
Adolescent
Adult
Aged
Female
Humans
Male
Middle Aged
Young Adult
Antineoplastic Combined Chemotherapy Protocols
Neoplasm Staging
Prognosis
Treatment Outcome

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
XJZT24QN04Xijing Hospital Research ProjectPubMed
2023LC2316Air Force Medical University Research ProjectPubMed

Source PubMed

Download CSV of grants

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136805888Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management.Semin Hematol2022https://conductscience.org/library/papers/36805888PubMed
236819187Characteristics and prognosis of distant metastasis after primary treatment for early-stage extranodal nasal-type natural killer/T-cell lymphoma from the China Lymphoma Collaborative Group database.EJHaem2023https://conductscience.org/library/papers/36819187PubMed
318676879Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring.Blood2008https://conductscience.org/library/papers/18676879PubMed
424495590Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma.Int J Radiat Oncol Biol Phys2014https://conductscience.org/library/papers/24495590PubMed
532844695Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.Leuk Lymphoma2020https://conductscience.org/library/papers/32844695PubMed
626726970Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.Leuk Lymphoma2016https://conductscience.org/library/papers/26726970PubMed
722811078First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.Cancer2013https://conductscience.org/library/papers/22811078PubMed
825409913
Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.
Ann Hematol2015https://conductscience.org/library/papers/25409913PubMed
932449800Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study.Am J Hematol2020https://conductscience.org/library/papers/32449800PubMed
1026109206Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study.Blood2015https://conductscience.org/library/papers/26109206PubMed
1132152465
Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making.
Leukemia2021https://conductscience.org/library/papers/32152465PubMed
1232943751Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.Leukemia2021https://conductscience.org/library/papers/32943751PubMed
1312933580Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index.Blood2004https://conductscience.org/library/papers/12933580PubMed
1426873565A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.Lancet Oncol2016https://conductscience.org/library/papers/26873565PubMed
1532435928Development and validation of an 18F-FDG PET radiomic model for prognosis prediction in patients with nasal-type extranodal natural killer/T cell lymphoma.Eur Radiol2020https://conductscience.org/library/papers/32435928PubMed
1638288898Prognostic Value of 18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma.Korean J Radiol2024https://conductscience.org/library/papers/38288898PubMed
1729092951Computational Radiomics System to Decode the Radiographic Phenotype.Cancer Res2017https://conductscience.org/library/papers/29092951PubMed
1825697894Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study.Leukemia2015https://conductscience.org/library/papers/25697894PubMed
1936570690The Novel Prognostic Index Model of Combining Circulating Tumor DNA and PINK-E Predicts the Clinical Outcomes for Newly Diagnosed Extranodal NK/T-cell Lymphoma.Hemasphere2023https://conductscience.org/library/papers/36570690PubMed
2035726449A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort.Am J Hematol2022https://conductscience.org/library/papers/35726449PubMed

See all 27 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42414740

GET https://conductscience.org/api/papers/v1/42414740/references?page=2